What is HC Wainwright’s Estimate for Brainsway Q3 Earnings?

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – HC Wainwright lowered their Q3 2026 earnings per share estimates for Brainsway in a research report issued on Monday, August 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.12 per share for the quarter, down from their previous estimate of $0.13. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.34 per share. HC Wainwright also issued estimates for Brainsway’s Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.20 EPS, Q4 2027 earnings at $0.22 EPS and FY2027 earnings at $0.75 EPS.

Brainsway (NASDAQ:BWAY) last released its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%.

BWAY has been the subject of several other research reports. Zacks Research cut Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. BTIG Research lifted their price objective on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. LADENBURG THALM/SH SH upped their target price on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Weiss Ratings cut shares of Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 19th. Finally, New Street Research reiterated a “buy” rating on shares of Brainsway in a report on Friday, July 24th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.20.

Brainsway Stock Performance

Shares of BWAY stock opened at $14.52 on Tuesday. Brainsway has a 52-week low of $7.14 and a 52-week high of $17.40. The firm has a market capitalization of $583.56 million, a PE ratio of 33.00 and a beta of 1.24. The stock has a fifty day simple moving average of $15.21 and a two-hundred day simple moving average of $14.63.

Institutional Trading of Brainsway

Several hedge funds have recently made changes to their positions in the business. Masters Capital Management LLC raised its position in Brainsway by 65.0% during the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after purchasing an additional 650,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Y.D. More Investments Ltd boosted its stake in Brainsway by 136.6% during the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after buying an additional 157,042 shares during the period. Sei Investments Co. boosted its stake in Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after buying an additional 163,925 shares during the period. Finally, ARK Investment Management LLC bought a new position in Brainsway during the fourth quarter valued at $2,422,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.